Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Street View: Sun Pharma steady on specialty demand, but near-term growth seen slowing

** Indian drugmaker Sun Pharmaceutical Industries SUN.NS posted 26.2% y/y jump in Q4 profit, aided by strong demand for its specialty drugs

** Shares of SUN fall ~0.9%

STEADY GROWTH, BUT NEAR-TERM PRESSURE

** HDFC Securities ("Buy," PT: 2,120 rupees) sees continued strength in specialty drugs and India business, supported by key brands and new launches

** Emkay ("Add," PT: 2,000 rupees) says Organon turnaround may depend on external factors, adding the stock could see a pause in gains near PT

** Ambit ("Buy," PT: 2,100) says business is at an inflection point, with growth likely to pick up as branded and innovative medicines scale up

** Elara Securities ("Accumulate," PT: 2,085 rupees) cuts FY27 earnings on lower margin assumptions, citing slower ramp-up in key U.S. innovative products and tariff risks

 (Reporting by Bipasha Dey in Bengaluru)

 ((Bipasha.Dey@thomsonreuters.com;))

Recent news on Sun Pharmaceutical Industries

See all news